|Awarded On||February 18, 2015|
|Title||Varenicline and Combined NRT for Initial Smoking Cessation and Rescue Treatment in Smokers: A Randomized Pilot Trial|
|Award Mechanism||Individual Investigator Research Awards for Prevention and Early Detection|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Paul M Cinciripini|
|Cancer Sites||Bladder, Head and Neck, Lung and Bronchus, Myeloma, Ovary, Pancreas|
Smoking accounts for at least 30% of all cancer deaths and plays a role in causing 18 different cancers. Over 40% of smokers make a serious cessation attempt each year, but each year less than 3% of all smokers successfully quit. There are several medications to help people quit including varenicline (Chantix), bupropion (Wellbutrin) and nicotine replacement products such as the patch and lozenge. But not all people respond the same to these medications. The major challenge of tobacco dependence disorders is that effective treatment may require repeated quit attempts and changes in treatment strategy when quitting is not achieved. Currently, there is very little information available to guid...